Clinical Trials Directory
If you choose to join this study, you will:
- Get 2-6 cycles of Inotuzumab Ozagamicin, lasting 1 month per cycle
- Get Methotrexate on day one during cycle 1 and on day 28 of cycles 2, 4 and 6
- Get about 3-5 mL of blood collected prior to treatment and at three time points during cycle 1 and 4 time points during cycle 2
We are doing this study to find the most effective and safe dose of an experimental drug called LY3537982 (the study drug) for people who have NSCLC that has KRAS G12C mutations.
We are doing this study to find out how much skin should be removed from around a melanoma to lower the chances of the melanoma coming back. We don't have enough evidence to know exactly how much skin to remove around the melanoma to give people the best chance at a good outcome.
We are doing this study to find out if an experimental drug called mosunetuzumab (the study drug) is a safe and effective option for low burden follicular lymphoma. We want to know how well it works in comparison to rituximab, which is the standard drug used to treat people with this diagnosis.
We are doing this study to find out if an experimental drug called STK-012 (the study drug) is a safe and effective treatment for different types of cancer.
We are doing this study to help connect people with type 1 diabetes to research studies they may be eligible to join as participants.
We are doing this study to find out if it is better to give patients with low-risk breast cancer regional radiation therapy as part of their standard treatment after surgery or if it is better to not give radiation. Regional radiotherapy is currently the standard treatment after surgery for low-risk breast cancer but we do not know if it is necessary in all cases.